Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Guide

Compounded vs. FDA-Approved Peptides: What's the Difference?

Not reviewed by a licensed provider. Read our disclaimer

Last updated

When people talk about “peptide therapy,” they may mean an FDA-approved drug, a compounded medicine or something sold online with no oversight at all. These are not the same thing, even when the active ingredient has the same name. This guide explains the difference, how federal compounding rules work and where the 2026 changes stand as of November 13, 2026.

What “FDA-approved” means

An FDA-approved drug is a specific product with a label that lists the uses FDA approved, along with warnings and side effects. For example, Wegovy (semaglutide) is labeled for long-term weight reduction in certain people and to lower the risk of major heart events in certain adults.1

A compounded drug is different. FDA says compounded drugs carry more risk than approved drugs because they do not go through FDA review for safety, effectiveness or quality before they are sold.2 FDA also says compounded drugs should be used only when a patient’s needs cannot be met by an FDA-approved drug.3 Clinical trial results for an approved drug apply to that drug, not to a compounded version.

503A pharmacies and 503B outsourcing facilities

Federal law describes two kinds of compounders:

  • 503A pharmacies are state-licensed pharmacies (and licensed physicians) that compound for individual patients. They may use a raw “bulk” ingredient only if it has an official quality standard (a USP or NF monograph), is part of an FDA-approved drug, or is on FDA’s 503A bulks list. The ingredient must come from an FDA-registered maker with a certificate of analysis, a document listing test results. FDA adds substances to the list through formal notice-and-comment rulemaking.4
  • 503B outsourcing facilities make larger batches. They may compound from bulk only if the substance is on a separate 503B bulks list or the drug is on FDA’s shortage list.5

Pharmacies also may not regularly compound “essentially copies” of drugs that are already sold. FDA gives semaglutide mixed with vitamin B12 as an example of a product that may count as a copy.5

What happened with GLP-1 drugs

FDA declared the tirzepatide shortage over in December 2024, after re-evaluating an October 2024 decision, and the semaglutide shortage over in February 2025. The grace periods for compounders ended by mid-2025.5 On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need. A final decision was pending as of that page.6

FDA has also received reports of people injecting 5 to 20 times the intended dose of compounded semaglutide from multiple-dose vials, sometimes leading to hospital care. Confusion between milliliters, milligrams and “units” may have played a part.2

FDA’s bulk-substance categories and “nominations withdrawn”

While the 503A list is being built, FDA sorts nominated substances into categories:4

  • Category 1: enough information to evaluate. FDA does not intend to act against compounders using them while it decides.
  • Category 2: FDA has identified significant safety risks and would consider taking action.
  • Category 3: not enough information to evaluate.

Substances nominated on or after January 7, 2025, are not placed in any category.4

Many wellness peptides were once in Category 2. By April 22, 2026, the nominations for most of them had been withdrawn, including BPC-157, TB-500, MOTS-c, epitalon, semax and KPV. The nominations were withdrawn; FDA still lists its safety concerns, such as possible immune reactions, impurities and little or no human safety data.7 Some remain in Category 2. Kisspeptin-10 is listed for 503A pharmacies. Ipamorelin is still on FDA’s significant-safety-risk list for outsourcing facilities (503B), while its pharmacy (503A) nomination was withdrawn.7

The July 2026 vote and the October 2026 HHS draft policy

In July 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A list.8 FDA’s own reviewers had recommended against adding BPC-157. They found no studies giving it to people by the proposed routes and only one small trial, reported as a meeting abstract.9 The committee narrowly voted to recommend adding BPC-157, KPV and TB-500 (reported as 8–6 with 1 abstention) and MOTS-c (reported as 7–5 with 2 abstentions). The vote is not binding.10 FDA has posted no minutes or final decision.8

On October 30, 2026, HHS published a notice about six peptides. According to law-firm summaries of the draft, they are BPC-157, TB-500, KPV, MOTS-c, epitalon and semax, each in specific forms, such as injection only or nasal only.11 As of 13 Nov 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding these peptides in certain forms.12 This is not FDA approval, and FDA has not added them to its official list.128

According to law-firm summaries of the draft, the conditions include a patient-specific prescription, one active ingredient per product, ingredients from FDA-registered sources with a certificate of analysis, and evidence that oral products are absorbed. The same summaries say 503B outsourcing facilities are not covered.13 The notice says HHS may revisit the policy if safety or quality problems arise.12 Comments closed on 13 Nov 2026. As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.12

Key differences side by side

FDA-approved Compounded
FDA review for safety, effectiveness and quality before sale Yes No2
FDA-approved label with uses and warnings Yes No
Requires a prescription Yes Yes, from a licensed prescriber
Who makes it A drug maker A 503A pharmacy or a 503B outsourcing facility

Questions to ask about a compounded peptide

  • Is there an FDA-approved version of this medicine? If so, why are you recommending the compounded one?
  • Which pharmacy makes it? Is it a 503A pharmacy or a 503B outsourcing facility, and is it licensed to dispense in Florida?
  • Where does this peptide stand on FDA’s category lists today?
  • Is it a single-ingredient product, or is something added?
  • How is the dose measured, and will someone show me how to draw it up?

See how to vet a peptide clinic and whether peptides are legal in Florida. Products sold “for research use only” are a third, riskier category, covered in our guide to research chemical peptide risks.

Footnotes

  1. Novo Nordisk. WEGOVY (semaglutide) injection and tablets. Prescribing information. Revised June 2026. Accessed November 2026. https://www.novo-pi.com/wegovy.pdf ↩

  2. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Content current July 26, 2024. Accessed November 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded ↩ ↩2 ↩3

  3. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current October 1, 2026. Accessed November 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↩

  4. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act. Content current May 14, 2026. Accessed November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act ↩ ↩2 ↩3

  5. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current April 1, 2026. Accessed November 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize ↩ ↩2 ↩3

  6. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement. Content current April 30, 2026. Accessed November 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list ↩

  7. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current April 22, 2026. Accessed November 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks ↩ ↩2

  8. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Content current August 6, 2026. Accessed November 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 ↩ ↩2 ↩3

  9. U.S. Food and Drug Administration. FDA briefing document: BPC-157-related bulk drug substances. Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. Accessed November 2026. https://www.fda.gov/media/193343/download ↩

  10. Jacobus N. FDA panel votes to loosen restrictions for four peptides. Pharmaceutical Executive. July 24, 2026. Accessed November 2026. https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides ↩

  11. Klock SM, Werner MJ, Crossan SS, et al. HHS issues interim enforcement discretion policy for compounding. Holland & Knight alert. November 4, 2026. Accessed November 2026. https://www.hklaw.com/en/insights/publications/2026/11/hhs-issues-interim-enforcement-discretion-policy-for-compounding ↩

  12. U.S. Department of Health and Human Services, Office of the Secretary. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (notice of availability). Fed Regist. 2026;91(209):68526-68527. Published October 30, 2026. Accessed November 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances ↩ ↩2 ↩3 ↩4

  13. Sklamberg H, Kumar D, Trentacost E. HHS announces draft enforcement discretion policy paving way for pharmacies. Arnold & Porter advisory. November 2, 2026. Accessed November 2026. https://www.arnoldporter.com/en/perspectives/advisories/2026/11/hhs-announces-draft-enforcement-discretion-policy-paving-way-for-pharmacies ↩

Frequently asked questions

Is a compounded peptide the same as the brand-name drug?

No. It may contain the same active ingredient, but compounded drugs do not get FDA review for safety, effectiveness or quality before they are sold. FDA warns against claims that a compounded drug is the same as an approved one.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy compounds for individual patients and may use only certain bulk ingredients. A 503B outsourcing facility makes larger batches and may compound from bulk only if the substance is on its own list or the drug is in shortage.

Can pharmacies still compound semaglutide or tirzepatide?

FDA declared both shortages over, and the grace periods for compounders ended by mid-2025. FDA says pharmacies may not regularly make essentially copies of approved drugs, and in 2026 it proposed keeping outsourcing facilities from making these drugs from bulk.

Did FDA approve BPC-157 or other wellness peptides in 2026?

No. HHS published a draft, non-binding policy about not taking enforcement action against licensed pharmacies that compound six peptides in certain forms. That is not FDA approval, and FDA has not added them to its official list.

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today